Upcoming Presentation of Innovative CAR T Therapy at ASCO 2025 by Verismo Therapeutics
Upcoming Presentation of Innovative CAR T Therapy at ASCO 2025 by Verismo Therapeutics
Verismo Therapeutics, a pioneering company in the realm of CAR T-cell therapies, has announced significant details regarding their upcoming poster presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting set to occur from May 30 to June 3, 2025, in Chicago, Illinois. The focus of this presentation will be on their innovative KIR-CAR platform, which is not just advancing the field of cancer treatment but also offers hope for patients struggling with specific types of cancer.
Dr. Janos L. Tanyi, MD, PhD, leading the STAR-101 Phase 1 clinical study, will provide insights into the ongoing trials during the session dedicated to gynecologic cancers. This clinical trial encompasses a first-in-human multicenter, open-label study designed to evaluate the safety, feasibility, and preliminary efficacy of their novel therapy, SynKIR-110. This therapy is targeted at patients with advanced mesothelin-expressing tumors, which includes challenging cases like ovarian cancer, mesothelioma, and cholangiocarcinoma, specifically those patients who have previously undergone at least one line of systemic therapy.
The importance of the STAR-101 trial cannot be overstated, particularly as ovarian cancer continues to present daunting treatment challenges. Traditional options have often fallen short, leaving many patients with limited choices. Dr. Tanyi emphasized the potential impact of the SynKIR-110 therapy, stating, "This study represents an important advancement for ovarian cancer, a disease with few available treatment options. This novel therapy could potentially change the treatment landscape by addressing critical limitations of existing CAR T-cell therapies."
Presentation Details
- - Location: Hall A – Posters and Exhibits
- - Poster Board Number: 522a
- - Abstract Number: TPS5630
- - Abstract Title: SynKIR-CAR T Cell Advanced Research (STAR)-101 Phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma
- - Presenting Author: Janos L. Tanyi, M.D., Ph.D.
- - Session Title: Gynecologic Cancer
- - Session Date: June 1, 2025, 9:00 AM - 12:00 PM CDT
Post-presentation, all interested parties can find the detailed poster on Verismo's website, ensuring broader access to this vital information.
Innovative KIR-CAR Platform
Verismo’s KIR-CAR platform distinguishes itself by employing a multi-chain CAR T-cell therapy designed to tackle solid tumors that have proven resistant to traditional CAR T approaches. Preclinical studies have highlighted its efficacy in enhancing T-cell functionality and longevity while mitigating exhaustion. By utilizing a unique signaling approach derived from natural killer cells, it has demonstrated a promising increase in anti-tumor activity within challenging tumor environments.
Furthermore, the KIR-CAR technology aims to address high unmet medical needs prevalent in advanced solid tumors and B-cell associated disorders. By enhancing T-cell persistence and overcoming tumor-induced immunosuppression, this innovation offers a robust alternative in the fight against persistent malignancies.
About Verismo Therapeutics
As a subsidiary of HLB Innovation, Verismo Therapeutics stands at the forefront of CAR T-cell research with their flagship products, SynKIR™-110 and SynKIR™-310, both currently in Phase 1 clinical trials. Their commitment to addressing areas of significant unmet medical need further establishes them as a leader in novel cancer therapies.
For more insights into their work and the KIR-CAR platform, please visit their official website at www.verismotherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements regarding clinical trials and product developments. Such statements, while based on current expectations, are subject to variability and uncertainties. Factors influencing outcomes may involve clinical trials, regulatory processes, and market conditions.
Conclusion
The upcoming presentation at ASCO 2025 signifies a crucial step in the journey of CAR T-cell innovations, especially in the treatment of hard-to-reach cancers. With advancements like Verismo's KIR-CAR platform, there is hope for a brighter future for patients facing daunting cancer diagnoses. As we eagerly await the findings from the STAR-101 trial, the potential of SynKIR-110 continues to inspire hope in the medical community and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.